Infectious Diseases News and Research

RSS

Biomagnetics and U.S. Government laboratory continue contract negotiations

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is in continuing contract negotiations to acquire the rights to Integrated Optical Biosensor System (IBOS) technology developed by one of the U.S. Government’s top national security research institutions.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

Researchers investigate individual's ability to get rid of Hepatitis C

More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.

17 Sep 2009

Study: Antiretroviral drugs may prevent HIV infection in women

Hopeful that some of the same antiretroviral (ARV) drugs used to treat HIV infection can also prevent it, researchers from the Microbicide Trials Network have enrolled the first participants into a new, large-scale clinical trial testing two approaches of the strategy in women.

17 Sep 2009

HIRC investigates the impact of infrastructure on pathogens and micro-organisms

The spread of swine flu and other infectious diseases could be dramatically reduced by revolutionising the way that the places we live in are designed and built.

17 Sep 2009

VOICE clinical study for testing the efficacy of two HIV prevention strategies

A new, large-scale clinical trial is examining whether antiretroviral medications normally used to treat HIV infection can also prevent HIV infection in women when applied as a vaginal gel or taken as oral tablets once daily.

16 Sep 2009

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.

16 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.

16 Sep 2009

Pan American Health Organization calls for preventing sickness to curtail health care costs

According to every major health organization, many costly and disabling conditions such as cardiovascular disease, cancer, diabetes and chronic infectious diseases are linked by common preventable risk factors -- smoking, poor dietary habits, physical inactivity and poor hygiene.

16 Sep 2009

Nomir publishes efficacy of the Noveondual-wavelength device against infectious disease pathogens

Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data.

16 Sep 2009

New mobile phone software helps remote analysis of data and map findings

New mobile phone software will help epidemiologists and ecologists working in the field to analyse their data remotely and map findings across the world, without having to return to the lab, according to research published in PLoS One today. The authors of the study, from Imperial College London, say the software will also enable members of the public to act as 'citizen scientists' and help collect data for community projects.

16 Sep 2009

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Pros and cons of HIV treatments in developing countries

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).

16 Sep 2009

GENova allies with academic institutions specializing in stem cell research

GENova Biotherapeutics Inc. ("GENova") today announced that it is forming strategic alliances with academic research institutions specializing in ground-breaking stem cell research.

16 Sep 2009

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

As a result of dominant media coverage of new epidemic threats such as swine influenza, other infection risks receive less public attention than they deserve. "We would like to bring to everybody's attention that the infectious diseases with the most severe consequences continue to be old acquaintances such as tuberculosis, HIV/AIDS, malaria and hepatitis C. About six million people worldwide die of these diseases every year," says Professor Dr. Dr. h. c. Stefan H. E. Kaufmann, Director of the Max Planck Institute for Infection Biology in Berlin, at the 2nd European Congress of Immunology ECI 2009.

16 Sep 2009

Opinion piece calls for enhanced U.S.-Russia health collaboration

While legislators in Moscow attempt to reform the Russian health system in a way that is "strikingly similar" to the reform process in the U.S. and "[g]iven the importance of the U.S.-Russia relationship ... our two countries have a historic opportunity to expand our health collaboration and, in so doing, improve our diplomatic ties," former U.S. Senate Majority Leader Bill Frist.

16 Sep 2009

CIDRAP summit to address employee protection measures during H1N1 pandemic

Business and healthcare leaders looking to fast-track preparedness for the H1N1 pandemic are gathering with infectious disease experts and Fortune 500 planners this month to determine how best to protect their employees and preserve their operations.

16 Sep 2009

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009